Pharmacokinetics and pharmacodynamics of insulin aspart in patients with Type 2 diabetes: Assessment using a meal tolerance test under clinical conditions
| Autor: | Hirofumi Misu, Kazuhide Ishikura, Hitoshi Ando, Yumie Takeshita, Seiichiro Kurita, Akio Fujimura, Ken-ichiro Kato, Akiko Shimizu, Shuichi Kaneko, Toshinari Takamura, Koumei Taji, Masafumi Uno |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty endocrine system diseases Physiology medicine.medical_treatment Type 2 diabetes Pharmacology Delayed hyperinsulinaemia Insulin aspart Pharmacokinetics Physiology (medical) Internal medicine Diabetes mellitus medicine Humans Hypoglycemic Agents Insulin Postprandial hyperlipidaemia Rapid-acting insulin analogues Aged Cross-Over Studies business.industry nutritional and metabolic diseases Middle Aged Postprandial Period medicine.disease Glucagon Crossover study Endocrinology Postprandial Diabetes Mellitus Type 2 Pharmacodynamics Female business medicine.drug |
| Zdroj: | Clinical and Experimental Pharmacology and Physiology. 39(6):528-534 |
| ISSN: | 0305-1870 |
| Popis: | Few studies have evaluated the pharmacokinetics of rapid-acting insulin analogues in patients with Type 2 diabetes, especially under clinical conditions. The aim of the present study was to assess both the pharmacokinetics and pharmacodynamics of insulin aspart in Type 2 diabetic patients who were being treated with the analogue alone. Meal tolerance tests with and without self-injection of a customary dose of insulin aspart (0.05-0.22 U/kg) were conducted in 20 patients in a randomized cross-over study. The dose of insulin aspart (per bodyweight) was significantly correlated with both the maximum concentration (r 2 = 0.59; P < 0.01) and area under the concentration-time curve for insulin aspart (r 2 = 0.53; P < 0.01). However, the time to maximum concentration (T max), which varied widely from < 60 to ≥ 120 min, was not associated with either dosage (r 2 = 0.02; P = 0.51) or body mass index (r 2 = 0.02; P = 0.57). Injection of insulin aspart exacerbated delayed hyperinsulinaemia after meal loading, mainly in patients with T max ≥ 120 min. With regard to pharmacodynamics, insulin aspart had favourable effects on postprandial hyperglycaemia, hyperglucagonaemia and hyperlipidaemia. The T max for this insulin analogue differed greatly between individuals and delayed hyperinsulinaemia was particularly exacerbated in patients with higher T max values. Identification of the factors contributing to interindividual variation in the absorption lag time is essential for improving the efficacy and safety of insulin aspart. © 2012 The Authors. Clinical and Experimental Pharmacology and Physiology © 2012 Blackwell Publishing Asia Pty Ltd. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|